Centiva Capital’s Seres Therapeutics MCRB Stock Holding History

Centiva Capital’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$481K	–	1475
2025 Q3	$481K	Buy	+25,000	New	+$399K	﹤0.01%	653

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Centiva Capital's MCRB Position: Q3 2024 in Review

Centiva Capital sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 9,390 shares — an estimated $136K sold.

Centiva Capital first reported a position in MCRB in Q2 2022 and held it in 2 quarters. The position peaked at $136K in Q2 2024. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

Centiva Capital reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 9,390 Seres Therapeutics shares in Q3 2024, an estimated $136K.
Centiva Capital first reported a position in Seres Therapeutics in Q2 2022 and held it in 2 quarters.
Centiva Capital's Seres Therapeutics position peaked at $136K in Q2 2024.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.